Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 1.00 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11155845 | 0.98 | TAAR1 (0.95) | TAAR1IDO1HTR2ACYP2A6HTR6 | |
| Hydrochloric Acid SCHEMBL29385879 | 0.98 | TAAR1 (0.95) | TAAR1IDO1HTR2ACYP2A6HTR6 | |
| SCHEMBL9330130 | 0.86 | TAAR1 (0.75) | TAAR1IDO1HTR2ACYP2A6MPO | |
| SCHEMBL31282089 | 0.84 | TAAR1 (0.72) | TAAR1IDO1MPOHRH1 | |
| SCHEMBL18396468 | 0.84 | TAAR1 (0.72) | TAAR1IDO1MPOHRH1 | |
| SCHEMBL32673432 | 0.82 | TAAR1 (0.69) | TAAR1IDO1MPOHRH1 | |
| SCHEMBL224549 | 0.81 | TAAR1 (0.70) | TAAR1HTR2ACYP2A6HTR6HTR1D | |
| SCHEMBL17151873 | 0.80 | TAAR1 (0.67) | TAAR1IDO1HTR2AHTR6CYP1A2 | |
| SCHEMBL1765174 | 0.79 | — | — | |
| SCHEMBL11010381 | 0.77 | TAAR1 (0.62) | TAAR1IDO1HTR2AHTR6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-118201447-A | Method for preparing perovskite film by passivating agent assisted domain-limited annealing and perovskite solar cell | 苏州大学 | 2024-06-14 | — | — | CN | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| US-20220213070-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-8853203-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-10-07 | — | — | US | disclosed |
| US-20140057902-A1 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-20140057902-A1 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| WO-2014030128-A1 | DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE | NOVARTIS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| US-20140057902-A1 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-4360511-A | Amines useful as brain imaging agents | MEDI-PHYSICS, INC. (US) | 1982-11-23 | — | — | US | disclosed |
| EP-0011858-A1 | Radioiodine containing amines, their preparation and their use as brain imaging agents | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | TAAR1 685/4885IDO1 1700/4885HTR2A 3716/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TAAR1 685/4885IDO1 1700/4885HTR2A 3716/4885 |
| US-20140057902-A1 | Diazepinone derivatives | ADRB1, ADRB2, BRD4 | TAAR1 248/4885IDO1 852/4885HTR2A 315/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TAAR1 686/4885IDO1 1712/4885HTR2A 3719/4885 |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | TAAR1 4519/4885IDO1 1019/4885HTR2A 4718/4885 |
| US-20220213070-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | TDO2, TFPI, PPIG | TAAR1 2843/4885IDO1 126/4885HTR2A 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.